{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:15:20Z","timestamp":1790306120648,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.intimp.2023.109704","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T17:04:47Z","timestamp":1674320687000},"page":"109704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation"],"prefix":"10.1016","volume":"116","author":[{"given":"Xingyan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2023.109704_b0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself"},{"issue":"6","key":"10.1016\/j.intimp.2023.109704_b0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1744666X.2018.1468753","article-title":"Immunogenicity of biologic therapies: causes and consequences","volume":"14","author":"Boehncke","year":"2018","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109704_b0015","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS J."},{"issue":"16","key":"10.1016\/j.intimp.2023.109704_b0020","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with Bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109704_b0025","doi-asserted-by":"crossref","first-page":"1995929","DOI":"10.1080\/19420862.2021.1995929","article-title":"The impact of immunogenicity on therapeutic antibody pharmacokinetics: a preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance","volume":"13","author":"Opolka-Hoffmann","year":"2021","journal-title":"MAbs"},{"issue":"15","key":"10.1016\/j.intimp.2023.109704_b0030","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","article-title":"Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis","volume":"173","author":"Maneiro","year":"2013","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.109704_b0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of biologic agents in rheumatology","volume":"17","author":"Strand","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109704_b0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2042098611406318","article-title":"Immunogenicity and other problems associated with the use of biopharmaceuticals","volume":"2","author":"Tovey","year":"2011","journal-title":"Ther. Adv. Drug Saf."},{"issue":"12","key":"10.1016\/j.intimp.2023.109704_b0045","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1089\/jir.2012.0139","article-title":"Manifestations of antidrug antibodies response: hypersensitivity and infusion reactions","volume":"34","author":"Vultaggio","year":"2014","journal-title":"J. Interferon Cytokine Res."},{"issue":"5","key":"10.1016\/j.intimp.2023.109704_b0050","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","article-title":"Immunogenicity of protein pharmaceuticals","volume":"108","author":"Dingman","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2023.109704_b0055","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front. Immunol."},{"issue":"424","key":"10.1016\/j.intimp.2023.109704_b0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta","volume":"10","author":"Lan","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109704_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000433","article-title":"Dual targeting of TGF-\u03b2 and PD-L1 via a bifunctional anti-PD-L1\/TGF-\u03b2RII agent: status of preclinical and clinical advances","volume":"8","author":"Lind","year":"2020","journal-title":"J. Immunother. Cancer."},{"issue":"5","key":"10.1016\/j.intimp.2023.109704_b0070","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2023.109704_b0075","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","article-title":"B-cell biology and development","volume":"131","author":"Pieper","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109704_b0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.intimp.2023.109704_b0085","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","article-title":"CD19: a promising B cell target for rheumatoid arthritis","volume":"5","author":"Tedder","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2023.109704_b0090","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2018","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.intimp.2023.109704_b0095","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nri2017","article-title":"Humanized mice in translational biomedical research","volume":"7","author":"Shultz","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.109704_b0100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.virol.2015.01.017","article-title":"Studies of retroviral infection in humanized mice","volume":"479\u2013480","author":"Marsden","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.intimp.2023.109704_b0105","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1146\/annurev.immunol.19.1.595","article-title":"B cell development pathways","volume":"19","author":"Hardy","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109704_b0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1084\/jem.154.1.138","article-title":"J chain biosynthesis in pre-B cells and other possible precursor B cells","volume":"154","author":"McCune","year":"1981","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.intimp.2023.109704_b0115","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(92)90029-C","article-title":"RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement","volume":"68","author":"Shinkai","year":"1992","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.intimp.2023.109704_b0120","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/intimm\/5.6.647","article-title":"Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus","volume":"5","author":"Chen","year":"1993","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2023.109704_b0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2018.09.008","article-title":"Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): a new era in cancer active immunotherapy","volume":"194","author":"Constantinidou","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109704_b0130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2023.109704_b0135","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and efficacy of a monovalent bispecific PD-1\/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.intimp.2023.109704_b0140","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1878-0261.13146","article-title":"Dual inhibition of TGF-\u03b2 and PD-L1: a novel approach to cancer treatment","volume":"16","author":"Gulley","year":"2022","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109704_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101960","article-title":"Human and mouse PD-L1: similar molecular structure, but different druggability profiles","volume":"24","author":"Magiera-Mularz","year":"2021","journal-title":"iScience"},{"issue":"8","key":"10.1016\/j.intimp.2023.109704_b0150","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.0712278105","article-title":"The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.intimp.2023.109704_b0155","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1080\/19420862.2016.1229721","article-title":"Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics","volume":"8","author":"Myzithras","year":"2016","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.intimp.2023.109704_b0160","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.intimp.2023.109704_b0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1749-6632.1995.tb26651.x","article-title":"Signaling difference between class IgM and IgD antigen receptors","volume":"766","author":"Kim","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"22","key":"10.1016\/j.intimp.2023.109704_b0170","doi-asserted-by":"crossref","first-page":"8459","DOI":"10.1073\/pnas.0603082103","article-title":"Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus","volume":"103","author":"Gitlin","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2023.109704_b0175","doi-asserted-by":"crossref","unstructured":"Y. G. Li, U. Siripanyaphinyo, U. Tumkosit, N. Noranate, A. N. A, Y. Pan, M. Kameoka, T. Kurosu, K. Ikuta, N. Takeda, S. Anantapreecha, Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells, Virol J. 9(2012) 114. https:\/\/doi.org\/10.1186\/1743-422x-9-114.","DOI":"10.1186\/1743-422X-9-114"},{"issue":"6","key":"10.1016\/j.intimp.2023.109704_b0180","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s11033-018-4427-x","article-title":"Monoclonal antibodies in cancer immunotherapy","volume":"45","author":"Kimiz-Gebologlu","year":"2018","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2023.109704_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2023.109704_b0190","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.intimp.2023.109704_b0195","doi-asserted-by":"crossref","first-page":"2014296","DOI":"10.1080\/19420862.2021.2014296","article-title":"Antibodies to watch in 2022","volume":"14","author":"Kaplon","year":"2022","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.intimp.2023.109704_b0200","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T12:07:23Z","timestamp":1719230843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":40,"alternative-id":["S1567576923000279"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109704","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109704"}}